Septerna (NASDAQ:SEPN) Trading Up 6.4% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN)’s stock price shot up 6.4% during mid-day trading on Tuesday . The company traded as high as $23.10 and last traded at $23.07. 84,226 shares traded hands during trading, a decline of 60% from the average session volume of 211,519 shares. The stock had previously closed at $21.69.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SEPN. Cantor Fitzgerald initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price target for the company. Wells Fargo & Company started coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company. JPMorgan Chase & Co. began coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, TD Cowen initiated coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company.

Septerna Stock Up 4.5 %

Insiders Place Their Bets

In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the transaction, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.